A decade of MMV mission working in partnership to discover, develop and facilitate access to new medicines for malaria

140 partners

45 countries
50 projects including:

2 medicines launched
2 medicines undergoing regulatory approval
2 medicines currently in clinical studies
2 compounds that will enter clinical studies by year-end
2 medicines launched

65 million courses delivered
Coartem-dispersible
MMV / Novartis

128 000 paediatric treatment courses
Injected artesunate
MMV / Guillin

160 000 children’s lives saved

9 000 children’s lives saved
1 child dies every 45 seconds from malaria
5 areas of strategic focus over the next 5 years

- improved access to ACTs
- treatments for children and pregnant women
- single-dose medicines
- medicines to pre-empt artemisinin resistance
- medicines that facilitate malaria elimination and eradication
Agenda

– Global plan for artemisinin resistance containment
– Medicines and the elimination of malaria
– Medicines for protection during pregnancy
– DHA/PQP: once-per-day treatment for uncomplicated malaria
– Artesunate injection: for management of severe malaria
– DHODH: structure based design of a new class of drugs
Thank you for your continued support

“I’m a patient investor”
Bill Gates

“The UK will not balance its books on the backs of the poorest”
David Cameron
British Prime Minister